Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer
Jianxia Li(The Affiliated Yongchuan Hospital of Chongqing Medical University), Yanhong Deng(Sun Yat-sen University), Yuqian Xie(Sun Yat-sen University), Zehua Wu(Shanghai Jiao Tong University), Hongbo Zheng(Genecast (China)), Xianrui Wu(Sun Yat-sen University), Longlong Gong(Genecast (China)), Zhi Xie(Fujian Agriculture and Forestry University), Jianwei Zhang(Capital Medical University), Yang Fu(Sun Yat-sen University), Ge Qin(Sun Yat-sen University), Fan Bai(Sun Yat-sen University), Huabin Hu(Sun Yat-sen University), Haoxian Ke(Sun Yat-sen University)
Cited by 33
Related Papers
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
|Journal of Clinical Oncology|2019|410
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial
|Journal of Clinical Oncology|2016|409
BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing
|Nature|2017|402